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Determination of the HLA-DM Interaction Site
on HLA-DR Molecules
erson et al., 1996), provide strong evidence for a direct
association between DM and MHC class II molecules
during peptide exchange. However, clues as to the
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*School of Medicine physical nature of these interactions remain sparse. The
acidic pH optimum of the interactions indicates a roleUniversity of Pennsylvania
Philadelphia, Pennsylvania 19104 for titratable functional groups (Sloan et al., 1995; Sand-
erson et al., 1996), and experiments using hydrophobic†Department of Pediatrics
Division of Transplantation Biology and Immunology fluorescent probes suggest a role for hydrophobic inter-
actions at the DM/DR interface (Ullrich et al., 1997). TheStanford University Medical Center
Stanford, California 94305 recently solved crystal structures of HLA-DM (Mosyak
et al., 1998) and its murine homolog, H-2M (Fremont et
al., 1998a), overall resemble those of classical MHC
class II molecules (e.g., Fremont et al., 1998b), exceptSummary
for the lack of a peptide binding groove. However, in-
spection of these structures yields no obvious clues asHLA-DM removes CLIP and other loosely bound pep-
tides from MHC class II molecules. The crystal struc- to how DM and DR interact.
In this study, we set out to identify point mutations intures of class II molecules and of HLA-DM have not
permitted identification of their interaction sites. Here, DR a or b chains that lead to a loss of interaction with
HLA-DM. We predicted that this should result in surfacewe describe mutations in class II that impair interac-
tions with DM. Libraries of randomly mutagenized DR3 accumulation of CLIP/DR complexes, as seen for cells
that lack DM altogether. An efficient screen for this phe-a and b chains were screened for their ability to cause
cell surface accumulation of CLIP/DR3 complexes in notype among cells with mutant DR3 molecules, fol-
lowed by careful biochemical characterization of infor-EBV-B cells. Seven mutations were associated with
impaired peptide loading in vivo, as detected by SDS mative mutants, allowed us to map a face of DR3 that
is critical for functional interactions with HLA-DM.stability assays. In vitro, these mutant DR3 molecules
were resistant to DM-catalyzed CLIP release and
showed reduced binding to DM. All mutations localize Results
to a single lateral face of HLA-DR, which we propose
interacts with DM during peptide exchange. Mapping of DM/DR Contacts
Random mutagenesis of HLA-DR3 (DRA*0101/
Introduction DRB1*0301) was employed to identify mutations that
decrease functional interaction with DM. Libraries of
HLA-DR molecules are synthesized in the endoplasmic mutant DR a and b chain cDNAs were introduced into
reticulum, where they associate with invariant chain (Ii). EBV-B cell lines lacking endogenous expression of the
A segment of Ii occupies the peptide binding groove of appropriate DR chain. These cells, carrying mutated DR
HLA-DR molecules (Ghosh et al., 1995), preventing other molecules, were screened for accumulation of CLIP, a
ligands from binding until delivery to endosomes (Roche hallmark of reduced DM function.
and Cresswell, 1990; Busch et al., 1995). Upon entry The recipient cell lines were two previously generated
into endosomes, Ii is degraded (Lotteau et al., 1990), EBV-B cell lines, 9.22.3 (DRA null) and 9.4.3 (DRB1 null)
leaving a nested set of peptides termed CLIP (class (Figure 1A). Retroviral transduction of the missing wild-
II–associated invariant chain peptides) in the groove. type DR a chain into 9.22.3 cells rescued surface HLA-
HLA-DM, an endosomal resident, nonclassical MHC DR expression, as measured by flow cytometry using
class II molecule (Sanderson et al., 1994), is required for the HLA-DR-specific mAbs, L243 (data not shown) and
efficient removal of CLIP from most HLA-DR molecules. ISCR3 (Figure 1B). Note that expression was restored
Therefore, CLIP/DR complexes accumulate at the sur- for both DR3 (DRA/DRB1*0301) and DRw52a (DRA/
face of cells lacking expression of functional DM (Rib- DRB3*0101) molecules, encoded by the two DR b chain
erdy et al., 1992; Fling et al., 1994; Morris et al., 1994; loci of the DR3 haplotype (Figure 1A). Similar results
Guerra et al., 1998) and of cells in which DM/DR interac- were obtained when the missing wild-type DRB1*0301
tion is disrupted (Mellins et al., 1994). Additionally, DM was transduced into 9.4.3 cells, except that endogenous
edits the peptide repertoire (Sloan et al., 1995; Katz et DRw52a (DRA/DRB3*0101) expression gave rise to sig-
al., 1996; Kropshofer et al., 1996; van Ham et al., 1996) nificant staining of untransfected cells with anti-DR
and stabilizes empty class II molecules (Denzin et al., mAbs (Figure 1B). Total DR levels increased about 2-fold
1996; Kropshofer et al., 1997; Vogt et al., 1997). after retroviral transduction.
The kinetics of DM-catalyzed peptide release from Untransduced 9.22.3 and 9.4.3 cells expressed low
purified MHC class II molecules in vitro (Sloan et al., but detectable levels of CLIP (measured by flow cytome-
1995), as well as coprecipitation experiments (Sand- try using the CLIP-specific mAb, CerCLIP.1; Figure 1B),
believed to be associated with endogenously expressed
DQ (R. C. D., unpublished data). Only a slight increase‡ To whom correspondence should be addressed (e-mail: rcdoebel@
mail.med.upenn.edu). in CLIP levels was noted after transfection of wild-type
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Figure 1. Cell Surface MHC Class II Expres-
sion and Peptide Loading of Mutant Cell Lines
(A) Experimental strategy. 9.22.3 lacks HLA-
DRa expression; DRa transfection restores
expression of HLA-DR3 and HLA-DRw52a,
containing b chains encoded by DRB1*0301
and DRB3*0101, respectively. 9.4.3 expresses
DRw52 but lacks DRB1*0301 and hence DR3
expression, which is reconstituted by trans-
fection of DRB1*0301. An asterisk (*) denotes
an HLA-DR molecule containing an introduced
chain with or without random mutations.
(B) Cell surface expression of HLA-DR and
associated CLIP on representative mutant
cell lines and wild-type controls stained with
anti-DR (ISCR3) or anti-CLIP (CerCLIP.1) mAbs.
Cells were stained with anti-DR (ISCR3; shaded
histogram) or anti-CLIP (CerCLIP.1; solid line)
or without primary Ab (dotted line), incubated
with FITC-conjugated goat anti-mouse IgG,
and analyzed by flow cytometry.
(C) Cell surface binding of mAbs CerCLIP.1,
6–39 (anti-DR3/CLIP) and 16.23. Bar graphs
represent ratios of median fluorescence in-
tensity of CerCLIP, 6–39, and 16.23 to that of
ISCR3, which corrects for slight variations in
DR expression. Shown are averages from
three independent experiments with stan-
dard deviation. Total surface expression of
HLA-DR as measured by ISCR3 binding was
similar for each set of cell lines (DRa mutants:
6 11%, DRb mutants: 68%). Upper panel,
DRa mutants (and wild-type control). Lower
panel, DRb mutants (and wild-type control).
DR3, so DM expression in these cells was sufficient to cated that these mutations stabilize the DR3/CLIP com-
plex (R. C. D. et al., unpublished data). However, a sec-allow release of CLIP from most wild-type DR molecules.
While DR3 molecules accumulate CLIP in the absence ond group of six mutants clusters on the lateral face of
DR3 that contains the N terminus of CLIP (Figure 2;of functional interaction with DM, DRw52a does not, due
to its low affinity for CLIP (Sette et al., 1995; unpublished Table 1).
data]. Thus, these cell lines allow sensitive screening
for high-CLIP mutants. Phenotypic Analysis
Although DM expression was observed in the mutantMutations were introduced into DRA and DRB1
cDNAs by error-prone PCR, yielding a library with a cells (data not shown), it was difficult to evaluate the con-
frequency of point mutations that was high enough to
contain every possible nucleotide substitution multiple
Table 1. HLA-DR Mutants Utilized in This Studytimes (see Experimental Procedures for details). To
screen for mutations that disrupt DM-DR interaction, we Chain Clone Mutation Amino Acid Substition
generated retroviral particles carrying mutant DRA and
DR alpha 3C5 T-G 226 F51V
DRB1 cDNAs and transduced them into 9.22.3 or 9.4.3 3E11 G-A 193 E40K
cells at a low multiplicity of infection (, 0.15) to avoid 3G4 G-A 16 V (220)a
T-C 227 F51Sintroduction of more than one cDNA per cell. HLA-DR
levels in the culture containing mutants were similar to DR beta 2B10 G-A 541 D152N
those found on cells reconstituted with wild-type DR 2E3 T-A 638 L184H
chains (data not shown). To select mutants, we used G-A 677 S197N
4C10 G-A 541 D152NFACS to clone the 0.1% cells displaying the highest
4E10 G-A 646 E187Klevels of CLIP. Upon rescreening of surviving clones
4F9 G-A 646 E187Kafter expansion, many retained a high-CLIP phenotype
EBV-B cell clones with high CLIP at the cell surface were isolated(Table 1; data not shown).
following introduction of randomly mutagenized DRA or DRB cDNATo identify mutations associated with the high-CLIP
libraries. cDNAs encoding the introduced DR chain were rescuedphenotype, the mutant cDNAs were rescued from the
by RT-PCR and sequenced. Nucleotides are numbered beginning
clones by reverse transcription and high-fidelity PCR. with the first nucleotide of the cDNA. Clones 3G4 and 2E3 harbored
DNA sequencing revealed the presence of single point two mutations each. Amino acids are designated by their one letter
mutations in most clones, and double mutations in a code. Amino acid numbering is from the first position in the mature
protein unless otherwise noted.few (Table 1; data not shown). Mapping of the mutations
a This mutation occurred in the segment encoding the signal se-on the published crystal structure of HLA-DR3 (Ghosh
quence and is numbered by counting backwards from the first aminoet al., 1995) revealed that one set of mutants clusters
acid in the mature DRa chain.
around the antigen binding groove; further analysis indi-
HLA-DR/HLA-DM Interface
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Figure 2. Mapping of Mutants onto the DR3/
CLIP Crystal Structure
Ribbon diagram representation of the HLA-
DR3/CLIP crystal structure. DRa chain is
shown in green, DRb in blue, and CLIP in
yellow. The amino (N) and carboxy (C) termini
of CLIP are labeled for orientation. Positions
in HLA-DR3 that correspond to deleterious
mutations described in this study are high-
lighted in red and labeled with the corre-
sponding substitutions. The branched struc-
ture protruding from DRb D152 represents
the addition of a glycan onto this residue in
the mutant bD152N. DRb S197N is repre-
sented as a red dot extending off the last b
chain residue (b Arg191) in the crystal struc-
ture. (*) Shown in purple is a mutant (b V186K)
identified through targeted mutagenesis of sev-
eral residues on the proposed interface. This
mutant caused elevated surface DR3:CLIP
levels (data not shown; see Discussion).
tribution of quantitative differences in DM and DR expres- CerCLIP.1 reactivity has been mapped to the CLIP N
terminus (Avva and Cresswell, 1994), located close tosion among the clones. Furthermore, other epigenetic
changes, such as insertional inactivation of genes im- some of the DR3 mutations described here (Figure 2).
To rule out the possibility that the mutations, ratherportant for antigen processing, in the immunoselected
clones could contribute to the observed phenotype. To than causing CLIP accumulation, improved interactions
between CerCLIP.1 and DR3, we measured binding withovercome these difficulties, the rescued single and dou-
ble mutants of DRA and DRB1 were reintroduced into a second mAb, 6–39, which binds a different epitope
that includes residues of DR3 and of the CLIP C terminus9.22.3 and 9.4.3 cells, respectively, generating poly-
clonal transduced lines in which any epigenetic variabil- (R. C. D. et al., unpublished data). Overall, lower levels
of staining were obtained using 6–39, but there was aity should average out. The contributions of the individ-
ual mutations in the double mutants (2E3, 3G4) were good correlation between staining intensities obtained
with the two antibodies. The antibody binding studiesanalyzed by site-directed mutagenesis.
Flow cytometry was used to assess surface expres- also revealed differences in CLIP accumulation, with
aE40K, aF51S, bD152N, and the double mutant,sion of mutant DR molecules and their associated pep-
tide loading phenotype (Figures 1B and 1C). All mutant bL184H/bS197N, being associated with stronger pheno-
types. Of the two mutations found in clone 2E3, bS197NcDNAs reconstituted DR expression to a similar extent
as wild-type, as measured using conformation-sensitive clearly made a smaller contribution when single mutants
were analyzed. Note that comparisons between a andmAbs specific for DRb (ISCR3; Figure 1B; data not
shown) or DRa (L243; data not shown). Thus, the muta- b mutants are difficult due to differences in the two
recipient cell lines. Nonetheless, all of the mutationstions did not impair HLA-DR assembly or surface ex-
pression. Staining with the CLIP-specific mAb, Cer- analyzed resulted in accumulation of varying amounts
of CLIP.CLIP.1, revealed increased CLIP/DR ratios in all mutants
over wild-type (Figures 1B and 1C). We also analyzed reactivity with 16.23, a mAb that
Immunity
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Figure 3. Mutant HLA-DR Molecules Fail to
Acquire SDS Stability
(A and C) Unboiled, nonreduced whole cell
lysates, prepared in 1% IGEPAL CA-630 de-
tergent, were resolved by 10% SDS-PAGE,
and Western blots were probed using DA6.147
(anti-DRa). The position of monomeric DRa
and SDS stable DR a/b dimers are indicated
by arrows. Molecular weight (kDa) standards
are shown on the right. Data are representa-
tive of at least three experiments. No immuno-
reactive higher MW bands were detected (not
shown). DRa and wild type control (A and B).
DRb mutants and wild type control (C and D).
(B and D) Bar graph representing the ratio of
SDS stable HLA-DR dimer to total HLA-DR
[Dimer/(dimer 1 monomer)] in (A) and (C), re-
spectively. Bands were quantified by densi-
tometry. The absolute proportion of SDS sta-
ble dimers in wild type and mutant cells varied
somewhat in different experiments, but the
mutant molecules were less stable than wild
type in all experiments (not shown).
binds to a subset of DR3 molecules that have undergone DR3 Mutants Are Resistant to DM In Vitro
The phenotypes associated with the DR3 mutations areDM-catalyzed peptide exchange (Morris et al., 1994;
Busch et al., 1998a). Although the differences in 16.23 consistent with a block in DM interaction, but do not
rule out other mechanisms, such as misrouting of HLA-staining were smaller than those found for anti-CLIP
mAbs, higher CLIP accumulation correlated with lower DR molecules, altered interaction with other accesory
molecules, or changes in CLIP affinity. To show a block16.23 staining and vice versa.
The most profound CLIP exchange defect was pro- in DM interaction directly, we examined the susceptibil-
ity of these mutant molecules to DM catalysis in vitro.duced by bD152N, which generated a consensus se-
quence for N-linked glycosylation. Reduced mobility of Mutant HLA-DR molecules were affinity purified after
transduction of the appropriate DRa and DRb chainsthis mutant b chain on SDS-PAGE gels confirmed the
presence of an additional glycan (cf. Figure 5B below). into the EBV-B cell line, 5.2.4, which lacks endogenous
expression of DM and all DR isotypes (Mellins et al.,
1991). The use of 5.2.4 transfectants allowed isolationMutant HLA-DR Molecules Are SDS Unstable
HLA-DR3/peptide complexes isolated from wild-type of pure mutant HLA-DR3/CLIP complexes without co-
purification of HLA-DRw52.cells are predominantly SDS stable, whereas the DR3/
CLIP complexes of DM null cells are mostly SDS unsta- To examine the effect of the mutations on DM suscep-
tibility in vitro, we measured dissociation of biotinylatedble (Mellins et al., 1990). SDS instability should be shared
by mutant HLA-DR3 molecules that fail to interact pro- CLIP (81–104) from purified mutant DR3 molecules in
the presence and absence of purified, recombinant solu-ductively with HLA-DM. To test this hypothesis, we com-
pared the SDS stability of mutant HLA-DR molecules by ble DM (sDM; Figure 4). For these studies, synthetic
CLIP was biotinylated at the C terminus, which is remoteWestern blotting without sample boiling, followed by
densitometry (Figure 3). All of the mutant HLA-DR mole- from the proposed DM interaction site (cf. Figure 2), to
avoid any interference of the label with DM catalysis.cules showed a reduction in the proportion of molecules
that resist SDS-induced chain dissociation compared In the absence of sDM, the half-lives of CLIP release
from all mutant HLA-DR molecules were comparable toto the appropriate wild-type cell line. Thus, despite the
presence of HLA-DM in these cells, these mutant mole- wild- type, or slightly faster (Figure 4B). Thus, the CLIP
accumulation seen in vivo cannot be explained by in-cules were unable to acquire a normal peptide repertoire
that confers SDS stability. creased stability of the CLIP-DR complex. In contrast,
HLA-DR/HLA-DM Interface
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The DM resistance exhibited by each mutant in vitro
correlated with CLIP accumulation and SDS instability
in vivo. We concluded that the HLA-DR mutants pre-
sented in this study, except perhaps bS197N, diminish
proper interaction with the ectodomains of DM.
Loss of DM Binding In Vitro
The simplest model to account for the diminished sDM
susceptibility is a decrease in the affinity of HLA-DM for
mutant HLA-DR molecules. Another possibility is that
the DM binding site and site of catalytic action are topo-
logically distinct, such that some mutations permit bind-
ing of the DM to DR but do not allow peptide release.
In order to examine these possibilities, we measured
binding of mutant DR molecules to DM by coprecipita-
tion. Purified mutant DR3/CLIP complexes were mixed
with full-length recombinant DM, DM molecules were
immunoprecipitated, and associated DR molecules
were quantified by Western blotting (Figure 5). On the
whole, the mutants bound less well to DM than wild-
type DR3. Quantitative comparisons between the cataly-
sis and binding assays are of limited value because of
the semiquantitative nature of the coprecipitation assay,
the use of different forms of recombinant DM in the two
assays, and the use of different incubation conditions.
Nonetheless, among the a chain mutants (Figure 5A),
loss of DM binding correlated with loss of susceptibility
to DM catalysis (cf. Figure 4): mutants aE40K and aF51S,
which showed a greater loss of DM susceptibility than
aF51V, also coprecipitated less well with DM. A similar
trend was seen for the b chain mutants (Figure 5B). DRa-
and DRb-specific mAbs gave qualitatively similar results
(Figure 5C), although the DRa-specific mAb was more
sensitive to the effects of the mutations. Interestingly,Figure 4. CLIP Dissociation from Mutant HLA-DR3 Molecules In Vitro
densitometric analysis of DM binding to the bS197N(A) Purified HLA-DR molecules (wild type and representative mu-
mutant suggests some loss of binding, in contrast to thetants) were loaded with C-terminally biotinylated CLIP [81–103]
lack of a phenotype for this mutant in CLIP dissociation(20 mM), unbound peptide was removed, and dissociation of labeled
CLIP was followed in the absence (open symbols) or presence (filled assays (cf. Figure 4C). Interaction with full-length DM
symbols) of 0.25 mM sDM at 378C, pH 5.2. Starting counts for each (used in the coprecipitation assay) rather than soluble
molecule were normalized to a value of 1, and single-exponential DM (used for CLIP release kinetics) may be required to
decay curves were fitted.
reveal the defect caused by this mutation in the connect-(B) Dissociation half-lives (t1/2) of DR3-CLIP complexes in the absence
ing peptide. Apart from this discrepancy, it was notof sDM are shown for each mutant. Experimental error is 65%.
possible within the accuracy of the assay to dissociate(C) DM-enhancement of DR3-CLIP dissociation is equal to the t1/2
in the absence of sDM divided by the t1/2 in the presence of sDM. loss of DM binding of the DR3 mutants from loss of
Data shown are representative of three or more experiments for catalysis.
each mutant.
Discussion
dramatic differences were seen when sDM was added.
Whereas CLIP dissociation from wild-type HLA-DR3 We have described the isolation of several novel HLA-
DR a and b chain mutants that accumulate CLIP due towas accelerated by a factor of nearly 15-fold, most of
the mutant HLA-DR molecules showed varying degrees a failure of the mutant molecules to interact productively
with HLA-DM.of resistance to enhancement of CLIP release by sDM
(Figure 4C). No enhancement was seen for aE40K, Most of the mutations do not appear to affect the
overall folding of HLA-DR. All of the substitutions occuraF51S, and bD152N, whereas partial defects were ob-
served for aF51V, bL184H, and bE187K. Only the weak at relatively surface-accessible positions (aE40, aF51,
and bE187 . 36%; bD152 and bL184 .15%; see Experi-mutant, bS197N, appeared indistinguishable from wild-
type. The discrepancy for this mutant between the slight mental Procedures) and are therefore unlikely to disrupt
important inter- or intrachain contacts. No mutation dis-CLIP accumulation observed in vivo and normal sDM
susceptibility in vitro likely is due to the position of the rupts surface expression, arguing that the mutant mole-
cules are folded well enough to escape retention by thebS197N mutation on the connecting peptide between
the b2 and transmembrane domains; this region is not quality control apparatus in the ER (Ellgaard et al., 1999).
Furthermore, conformation-specific antibodies recog-likely to influence the in vitro dissociation assay, which
is performed with soluble DM. nize these molecules equally (Figures 1B and 1C; data
Immunity
522
Figure 5. Mutant DR Molecules Are Impaired
in Their Ability to Bind DM
DR molecules with mutations in the DR a (A)
and b (B) chains were mixed with lysates of
insect cells containing recombinant full-
length DM. After incubation at 378C (pH 5.0,
1% CHAPS), DM molecules were immuno-
precipitated and associated DR molecules
quantified by Western blotting. Levels of in-
put DR and recovered DM were similar for all
immunoprecipitations (data not shown). The
asterisk (*) denotes the use of a second, inde-
pendently purified DR preparation in some
reactions. Note the decreased mobility of the
bD152N mutant b chain, which carries an ad-
ditional N-linked glycan.
(C) Densitometric quantitation of data pooled
from two independent experiments like that
shown in (A) and (B). Filled bars summarize
results obtained using anti-DRb (B10.a) and
open bars those from anti-DRa (DA6.147)
blots. Background-subtracted band intensi-
ties from film exposures in the linear range
were normalized to wild type DR3 (5 100%)
and corrected for variations in input DR and in
recovered DM as described in Experimental
Procedures. Qualitatively similar results were
obtained in three to six additional experiments,
although higher background seen in these ex-
periments precluded precise densitometry.
not shown), and all mutants have near-normal rates of and because a previously isolated mutation that causes
aberrant glycosylation of aN94 and poor interaction withCLIP release in the absence of DM (Figure 4B). A possi-
ble exception is the glycosylation mutant, bD152N, DM (Mellins et al., 1994; Sloan et al., 1995; Denzin et al.,
1996; Sanderson et al., 1996; R. B., unpublished data)which may well have a subtle conformational defect.
This mutant releases CLIP slightly but consistently faster was not found again in this study. However, extensive
site-directed mutagenesis of adjacent charged and hydro-than the other mutants (Figure 4B), and the mobility of
its a chain is somewhat reduced, suggesting alterations phobic residues on this face of DR3 has revealed only
one additional mutation (bV186K) that causes CLIP ac-of remote a chain glycans (data not shown). In any case,
the mapping information obtainable from this mutant is cumulation in vivo, so the map probably is not grossly
incomplete (A. P, unpublished data). As our screen islimited due to the large footprint of an N glycan.
As the mutations map to a common face on the DR biased against folding mutants, we may also have
missed mutations that disrupt the DM binding site whilecrystal structure (Figure 2) and most do not detectably
alter conformation, it is unlikely that the mutations influ- simultaneously destabilizing the structure of the DR3
molecule.ence DM interactions by changing the conformation of
a distant DM contact site. Aberrant transport of mutant
DR molecules to endosomes also is unlikely, because Characteristics of the DM Binding Site on HLA-DR
Our data agree with previous results tentatively implicat-normal generation of CLIP (a prerequisite of isolation of
high-CLIP mutants using CerCLIP.1) occurs only when ing this region of the molecule in interactions with DM:
the mAb CerCLIP.1 prevents DM-mediated CLIP releaseendosomal transport is intact. Rather, the CLIP accumu-
lation in mutant cells can be accounted for by the dimin- by binding to the N terminus of CLIP (Denzin and Cress-
well, 1995), and N-glycosylation of DRa residue 94 dis-ished interaction with DM, which was detectable by two
independent in vitro assays. Thus, we propose that the rupts DM/DR interaction (see above). However, each of
these results has inherent methodological limitations;mutations define the site at which DM binds DR during
peptide exchange. Our mapping likely remains incom- at best, both results yield a large footprint with little
information about the nature of the interaction.plete, because most mutations were isolated only once
HLA-DR/HLA-DM Interface
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Figure 6. Proposed Mechanism of DM Action
(A) View of pocket 1 of the HLA-DR3-CLIP
crystal structure and surrounding residues
(same orientation as Figure 2), showing the
cluster of hydrophobic amino acids connect-
ing the P1 pocket of the groove to the surface
exposed, DM-interacting residue, DRa F51.
Engagement of this residue by DM may trans-
mit a conformational change to the antigen
binding groove. The P1 residue of CLIP (M91)
is displayed in yellow, DRa residues are shown
in green (except aF51, shown in red), and
DRb residues are shown in blue.
(B) TCR view of the peptide binding groove.
The DM-interacting residues, DR aF51 and
bE40, are positioned close enough to aS53
to allow the hydrogen bonds extending from
this residue to the peptide backbone (boxed)
to be broken.
The mutations presented here span the entire length that DM interacts with the same surface on all MHC
class II molecules. However, limited polymorphism doesof the HLA-DR ectodomains and are present on both
chains. Binding is thus likely to involve a large surface exist in DRb on the surface proposed here to interact
with HLA-DM. These polymorphisms could produce al-area on HLA-DR (and HLA-DM) and may occur at an
angle, across the b2 and a1 domains of DR. Additionally, lelic differences in DM susceptibility. Additionally, there
are several amino acid differences in the a and b chainsa small contribution appears to be made by interactions
between the connecting peptides of DM and DR. There of both HLA-DP and -DQ that have the potential to affect
DM activity, based on their localization to the proposedwas a conspicuous lack of disruptive mutations in the
a2 domain, even after screening several additional site- DM interaction site. Further work with these other MHC
class II molecules will be needed in order to determinedirected mutants (charge reversal mutations at aGlu98,
aArg100, and aGlu101), suggesting that this domain may whether these differences can alter peptide loading and
presentation.not interact much with DM. Surface expression was nor-
mal for these DR mutants, arguing against the possibility The putative DM binding site is distinct from the class II
binding sites for SEB, TSST-1, and CD4. SEB bindsthat a2 domain mutations are unusually prone to causing
folding defects. The previously described a2 domain solely to the a1 domain, primarily to the loops (turns) of
the b-pleated sheet (Jardetzky et al., 1994). The closestmutant, aP96S, acts largely, if not entirely through addi-
tion of a bulky glycan at residue aN94, directly adjacent residue in the DM binding site is aE40K, but this residue
is well removed from SEB contact. The TSST-1 bindingto the b chain (Mellins et al., 1994; Guerra et al., 1998).
The DRa chain is monomorphic, and the majority of site overlaps that of SEB and does not involve the DM
binding site (Kim et al., 1994). CD4 binds to the a2 andpolymorphisms occurring among HLA-DR b chain al-
leles localize to the peptide binding cleft. The homology b2 domains of MHC class II molecules (Konig et al.,
1992) but on the opposite face from the one proposedamong HLA-DR, -DP, and -DQ is also highest in regions
outside of the peptide binding groove. DM itself is rela- here. The DM/DR interface is also different from that
between tapasin and MHC class I molecules (Suh et al.,tively nonpolymorphic, as is its murine homolog H-2M
(Bodmer et al., 1995; Hermel et al., 1995). It is thus likely 1999).
Immunity
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Model for DM-Catalyzed Peptide Release interaction. These mutants have allowed us to define a
Our observations that exposed glutamic acid residues DM binding site on a lateral face of HLA-DR comprising
with expected pKa values between 4.5 and 6 are part of exposed acidic and hydrophobic residues. Our results
the face of DR3 that interacts with HLA-DM (Figure 2) suggest a mechanism by which DM binding to MHC
and are involved in DM interactions (Figures 4 and 5) class II molecules translates into peptide release via
may help explain the acid optimum of DM catalysis and disturbance of key interactions between the peptide and
binding (Sloan et al., 1995; Sanderson et al., 1996). A model MHC class II molecule near the P1 pocket.
involving direct interactions between charged residues of
DM and DR is also compatible with the differential ef- Experimental Procedures
fects of salt on DM-catalyzed peptide binding to DR0401
Cell Lines and Antibodiesmolecules at neutral and endosomal pH (R. B., unpub-
The following mutant EBV-B cell clones, all derived from a commonlished results). However, pH may also regulate DM/DR
progenitor, and their culture conditions, have been described pre-
interactions indirectly through effects upon DM and DR viously. 9.22.3 lacks expression of DRa but expresses two DR b
conformation (Runnels et al., 1996; Ullrich et al., 1997). chains (DRB1*0301 and DRB3*0101) (Pious et al., 1985). 9.4.3 lacks
Several lines of evidence have led to the notion that DRB1*0301 expression but expresses DRa and the DRB3 gene
product. The cell line 5.2.4 lacks expression of DR a, both b chains,DM interacts best with open conformers of DR that are
as well as HLA-DM (Mellins et al., 1991). `NXA cells (kind gift ofcapable of rapid peptide release (Denzin et al., 1996;
G.P. Nolan, Stanford University) were grown in DMEM supplementedKropshofer et al., 1997; McFarland et al., 1999). Stabili-
with 10% heat-inactivated calf serum, 2 mM L-glutamine, and 1 U/ml
zation of such a conformer by DM provides a simple Penicillin/Streptomycin (Life Technologies, Gaithersburg, MD).
mechanism that could explain the ability of DM to cata- The following antibodies have been described previously: L243
lyze peptide exchange as well as to chaperone empty (Lampson and Levy, 1980), CerCLIP.1 (Avva and Cresswell, 1994),
ISCR3 (Watanabe et al., 1983), 47G.S4 (Schafer et al., 1996), DA6.147class II molecules. In this study, we have been unable to
(Guy et al., 1982), 16.23 (Johnson et al., 1982), B10.a (Clark andidentify mutations that affect DM-catalyzed CLIP release
Yakoshi, 1984), 5C1 (Sanderson et al., 1996), and 11323 (DM; giftfrom DR but not DM/DR binding. Although the number
of D. Zaller, Merck Research Laboratories; cf. Busch et al. (1998a).of mutations remains small, these results suggest that
6-39 is a murine IgG1 that recognizes DR3/CLIP complexes (E. D. M.,
stable DM binding and catalysis of peptide release are M. Amaya, Z.-K. Pan, S. Lawrence, and Y. Paterson, unpublished data).
highly concerted processes. In line with this view, we
have recently observed that mutations in the antigen Cloning, PCR, and DNA Sequencing/DRA and DRB Constructs
binding groove that stabilize CLIP/DR3 complexes also Wild-type cDNAs encoding either DRA1*0101 (with 3 silent muta-
tions) or DRB1*0301 were PCR-amplified using Pfu DNA polymerasereduce binding to DM (R. C. D. et al., unpublished data).
under standard conditions, from pRC/CMV-DRA (kind gift of Ming-derElucidation of the conformational changes induced
Y. Chang, North Shore University Hospital-NYU School of Medicine)by DM binding will require crystallographic studies of
or pLNC5-DRB1*0301 (kind gift of William W. Kwok, Virginia MasonDM/class II complexes. However, the notion that small
Research Center), respectively. The primers DRA-U1 (sense, 59 CGA
conformational changes may suffice to release the pep- GAAGGATCCACTCCCAAAAAGAGCGCGCCCAA 39) and DRA-L2
tide is consistent with our observation that residues (anti-sense, CAGTGATCTGAATTCTAAGAAACACCATCACCTCC) were
critical for DM/DR interaction were surface exposed in used to amplify the DRA*0101 cDNA; for DRB1*0301 we used DR3B-
U1 (sense, CTGCTCGGATCCCTGGTCCTGTCCTGTTCTCC) andthe crystal structure of DR3/CLIP and some were lo-
DR3B-L2 (anti-sense, CCTCTCGAATTCAAGAATAACAGCCAGGAGcated near the groove, suggesting that major conforma-
GGAAAGCTT) (all primers were made by Life Technologies). PCRtional adjustments are not required. Although breakage
products were cloned into the retroviral vector, pBMN-IRES-neorof hydrogen bonds may be a key step in DM-catalyzed
(kind gift of G. Nolan, Stanford University), using primer-encoded
peptide release (Weber et al., 1996), our results provide 59 BamHI and 39 EcoRI restriction sites.
no evidence that DM interacts directly with DR residues cDNAs were mutagenized using error-prone PCR, using the fol-
that comprise the hydrogen-bonding network (Figures lowing conditions (J. Caldwell, personal communication). Template
cDNA (pBMN-DRA wt-IN or pBMN-DRB wt-IN; 10 fmol) was ampli-2 and 6). Any weakening of hydrogen bonds by DM may
fied using 10 pmol each of sense and antisense primers (pBMN-U1,instead involve indirect effects. One mechanism for this,
AAGTAGACGGCATCGCAGCTT; and pBMN-L1, CCAGACCAACTGpreviously suggested by Mosyak et al. (1998), is sup-
GTAATGGTA), and 2.5 U Taq polymerase (Life Technologies) in 7 mMported by our identification of two different mutations MgCl2, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 0.01% gelatin (w/v),
at position DR aF51 that impair DM interaction. This 5% DMSO (v/v), 0.2 mM dGTP, 0.2 mM dATP, 1 mM dTTP, and 1 mM
residue is exposed on the DM contact interface of HLA- dCTP. Amplification was carried out using 30 cycles of denaturation
DR at one end of a cluster of hydrophobic residues (948C, 1 min.), annealing (508C, 1 min.), and extension (728C, 1.5
min.), followed by 10 min. at 728C. Libraries were digested withthat communicate with the P1 sidechain pocket of the
BamHI and EcoRI and recloned into pBMN-IRES-neor. For both aantigen binding groove (Figure 6A). Furthermore, this
and b chain libraries, about 150,000 colonies were obtained. Se-residue could act as a lever by which HLA-DM moves
quencing of ten randomly chosen clones each revealed mutation
the extended strand including residues 51–53 such that rates of about 4–5 3 1024 mutations per nucleotide. The probability
the two-hydrogen bonds between Ser 53 and the pep- P that k mutations will occur in a sequence of length n at a given
tide backbone are broken (Figure 6B). Residue aE40, mutation rate, e, was calculated as: P 5 (n!/[(n-k)!k!)]ek(1-e)n-k). By
on the adjacent strand, could also participate in this this estimate, 70% of the libraries should be wild-type, about 23%
should have a single mutation, and a small minority should havelever-like action. An open question is whether in addition
two or more mutations. Each of the z2400 single point mutationsto such local movements, the DM contact residues in the
should be represented an average of 16 times in the libraries.b2 domain are involved in more global conformational
We electroporated ligation reactions into Electromax DH10B cells
changes or whether they serve only to provide intermo- (Life Technologies) using a BioRad Gene Pulser (0.1 cm cuvette, 2.5 kV,
lecular contacts that contribute to affinity. 100 V, 25 mF) and plated onto ten 15 cm LB agar plates containing
In conclusion, we have developed an efficient screen 50 mg/ml ampicillin, yielding z1.5 3 105 colonies. Plasmid DNA was
isolated without further expansion to prevent bias in the library.for mutant HLA-DR molecules with defective HLA-DM
HLA-DR/HLA-DM Interface
525
cDNAs encoding the mutant HLA-DR chain of interest were res- fected Drosophila cells as described (Sloan et al., 1995; Busch et
al., 1998b).cued from cells by RT-PCR (Life Technologies) using the vector-
derived primers, pBMN-U1 and pBMN-L1. They were cloned into
In Vitro Peptide Dissociation Assaysthe original pBMN-IRES-neor vector and sequenced at the Stanford
Human CLIP with a C-terminal lysine [LPKPPKPVSKMRMATPLLMPAN facility.
QALPK] was synthesized, derivatized with long-chain biotin, andSite-directed mutagenesis was done by overlap extension PCR
purified by HPLC (Genemed Synthesis, Inc., South San Francisco,(Ho et al., 1989), using Pfu polymerase. Mutant cDNAs were cloned
CA). Labeled CLIP was incubated with purified mutant DR3 in theinto pBMN-IRES-neor and verified by sequencing.
presence of 1% n-octyl-glucoside (Boehringer Mannheim, Indianap-
olis, IN) for 24 hr at 378C in citrate-phosphate buffer containing 0.5%Molecular Modeling
IGEPAL CA-630, 1% BSA, and 0.05% NaN3, and 1mM PMSF (pH 5.2).DR3-CLIP images were generated from PDB coordinates (accession
Peptide/DR complexes were separated from free peptide using acode 1A6A) using WebLab ViewerLite v.3.5 software (Molecular Sim-
Sephadex G50-Superfine spin column and diluted to z12 nM inulations Inc., San Diego, CA). Surface accessibility was calculated
citrate-phosphate buffer (as above without n-octyl-glucoside, pH 5.2).
using Swiss PDB viewer v.3.51 software (http://www.expasy.ch/
Unlabeled CLIP was added to a final concentration of 5 mM to
spdbv/mainpage.html). Using this algorithm, only z16% of all HLA-
prevent rebinding of dissociated biotinylated CLIP, and dissociation
DR3 residues in the crystal structure have surface accessibility
was allowed to proceed at 378C with or without 0.25 mM soluble HLA-
.36% and z41% of all residues have .15% surface accessibility.
DM for various times. At each time point, reactions were stopped by
adding 2 volumes of ice-cold 50 mM Tris-HCl (pH 8.2), 150 mM
Retroviral Transduction NaCl, 0.5% IGEPAL CA-630, 0.5% BSA, and 0.05% NaN3. Neutral-
Production of amphotropic retrovirus using the pBMN vectors and ized reaction mixtures (100 ml) were transferred to L243-coated,
`NXA packaging cell line was performed as described previously blocked flat-bottom 96-well microtiter plates. After 2 hr of capture
(Guerra et al., 1998) with minor modifications. In brief, 8 mg of plas- of DR complexes at 48C, plates were washed in 200 ml PBS, 0.05%
mid DNA was transfected into 2.5 3 106 `NXA cells by calcium Tween-20, and 0.05% NaN3. DR-bound biotinylated peptide was de-
phosphate precipitation (Life Technologies). Twenty-four hours after tected by addition of 0.1 mg/ml Eu31-conjugated streptavidin (EG&G
transfection, cells were incubated in fresh media at 328C. Retroviral Wallac, Gaithersburg, MD) in blocking buffer at 48C for 1 hr. After
supernatant was harvested at 48 hr posttransfection and centrifuged further washes, enhancement solution (100 ml; EG&G Wallac) was
for 5 min at 500 3 g to remove any cells. EBV-B cells were resus- added, and time-resolved fluorescence of Eu31 was detected using
pended in the retroviral supernatant at a density of 5 3 105 cells/ a DELFIA 1234 fluorescence plate reader (EG&G Wallac).
ml in the presence of 4 mg/ml polybrene (Sigma, St. Louis, MO).
Following a 24 hr incubation at 328C, transduced cells were washed DM/DR Binding Assay
Drosophila cells transfected with full-length DM cDNAs (DMA*0101/and selected in media containing 1 mg/ml G418 (Life Technologies).
DMB*0101 (Busch et al., 1998b) under the control of the metallothio-
nein promoter were induced with 1 mM CuSO4 for 24 hr and lysedFlow Cytometry and FACSorting
in PBS, 1% CHAPS, plus protease inhibitors, at a density of 5 3Indirect staining of cells was performed as described (Busch et al.,
107 cells/ml. DM concentration in the lysate (estimated by Western1998a). Cells were analyzed on a FACScan flow cytometer using
blotting using purified soluble recombinant DM as a standard) was
CellQuest v.3.1 software (Becton Dickinson, San Jose, CA).
z90 ng/ml. DM-containing lysate (1–2 ml) was mixed with purified
For fluorescence-activated cell sorting, 107 cells were stained first
wild-type and mutant DR3 molecules (100–500 ng) in 50–60 ml reac-
with the mAb CerCLIP.1 and then a goat anti-mouse IgG-FITC (Cal-
tion buffer [50 mM sodium acetate (pH 5.0), 150 mM NaCl, 1%
tag, Burlingame, CA) under sterile conditions and sorted on a Vantage CHAPS, 0.5% BSA, 0.05% NaN3, and protease inhibitors]. After incu-FACSorter (Becton Dickinson) at the Stanford Shared FACS Facility. bation at 378C for 1–2 hr, reaction mixtures were immunoprecipitated
Cells with the highest levels of surface CLIP (arbitrarily set to the with an anti-DM antiserum (11323; 2 ml serum bound to 15 ml protein
brightest 0.1%) were sorted into 96-well flat-bottom plates contain- A-sepharose) for 1 hr at 48C. Immunoprecipitates were separated
ing either fibroblast-conditioned RPMI or z105 fibroblasts in RPMI. by 12% SDS-PAGE, and DM-associated DR3 molecules were de-
tected by Western blotting using the DRa-specific mAb, DA6.147,
or the DRb-specific mAb, B10.a. Blots were reprobed with the DMb-Western Blotting
specific mAb, 47G.S4, or with the DMa-specific mAb, 5C1, to checkWestern blotting of cell lysates was performed as described pre-
for consistent recovery of DM. To ensure that comparable levels ofviously (Busch et al., 1998a). In brief, cells were washed, lysed in
all mutant DR molecules were used, the input DR molecules were1% IGEPAL CA-630 at of 107 cells/ml (1 hr, 48C), and cleared of
also compared by Western blotting on the day of each assay. Densi-nuclei and debris. Nonreducing Laemmli SDS-PAGE sample buffer
tometry was performed using a BioRad GS-710 densitometer. Afterwas added, and lysates were left unboiled (48C) or boiled (10 min.,
subtraction of background, band intensities for the mutants were958C) prior to loading on 10% SDS-PAGE gels. Separated proteins
normalized to wild-type (5 1.0) and corrected for variation in recov-were transferred to PVDF (Immobilon P, Millipore, Bedford, MA).
ered DM and input DR using the following formula:Blots were developed using goat anti-mouse IgG HRP conjugate and
an enhanced chemiluminescence substrate (Renaissance; Dupont
Corrected intensity 5 100 3 (normalized DR band intensity from coIP).
NEN, Boston, MA). Band intensities were quantified on light film (normalized input DR intensity) 3 (normalized recovered DM intensity)
exposures using a GS-710 densitomer and Quantity One software
(BioRad, Hercules, CA).
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